The Economics of Cardiovascular Disease in the United States

Critical Care Clinics

Volumn 28, Issue 1, 2012, Pages 77-88

  Chen, Jie ^a   Rizzo, John A ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Cost effective treatment; Economic burden; Medical treatment; Surgical treatment

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CHOLESTEROL; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PACLITAXEL; PRAVASTATIN; SIMVASTATIN;

AFRICAN AMERICAN; AGING; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ASIAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONGENITAL HEART MALFORMATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DIET; DRUG ELUTING STENT; ELECTROPHYSIOLOGY; ETHNICITY; EXERCISE; FAMILY HISTORY; FOLLOW UP; GROUPS BY AGE AND SEX; HEALTH CARE COST; HEART FAILURE; HEART GRAFT; HEART INFARCTION; HEART REHABILITATION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MEDICAID; MEDICAL CARE; MEDICARE; MORBIDITY; MORTALITY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SMOKING; UNITED STATES;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SURGICAL PROCEDURES; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; UNITED STATES;

EID: 82955184566     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2011.10.007     Document Type: Review

References (57)

1. Heidenreich P., Trogdon J., Khavjou O., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
2. Trogdon J.G., Finkelstein E.A., Nwaise I.A., et al. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract 2007, 8:234-242.
3. Lloyd-Jones D.M., Hong Y., Labarthe D., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association's Strategic Impact Goal through 2020 and beyond. Circulation 2010, 121:586-613.
4. Cohen J.W., Krauss N.A. Spending and service use among people with the fifteen most costly medical conditions, 1997. Health Aff (Millwood) 2003, 22:129-138.
5. Russell M.W., Huse D.M., Drowns S., et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998, 81:1110-1115.
6. Roger V., Go A., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
7. Pleis J.R., Ward B.W., Lucas J.W. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. Vital Health Stat 10. No. 249;2010 Accessed September 21, 2011. http://www.cdc.gov/nchs/data/series/sr_10/sr10_249.pdf.
8. Incidence and prevalence: 2006 chart book on cardiovascular and lung diseases 2006, National Institutes of Health; National Heart, Lung, and Blood Institute, National Heart, Lung, and Blood Institute, Bethesda (MD), Accessed September 16, 2011. http://www.nhlbi.nih.gov/resources/docs/06a_ip_chtbk.pdf.
9. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
10. Sekikawa A., Kuller L.H. Striking variation in coronary heart disease mortality in the United States among black and white women aged 45-54 by state. J Womens Health Gend Based Med 2000, 9(5):545-558.
11. Soni A. Personal health behaviors for heart disease prevention among the U.S. adult civilian noninstitutionalized population, 2004. MEPS Statistical Brief No. 165 March 2007, Agency for Healthcare Research and Quality, Rockville (MD), Accessed September 27, 2011. http://meps.ahrq.gov/mepsweb/data_files/publications/st165/stat165.pdf.
12. Thom T., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113(6):e85-e151.
13. Mensah G., Brown D. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007, 26(1):38-48.
14. Hodgson T.A., Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care 2001, 39:599-615.
15. Druss B.G., Marcus S.C., Olfson M., et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood) 2001, 20:233-241.
16. Tarride J., Lim M., DesMeules M., et al. A review of the cost of cardiovascular disease. Can J Cardiol 2009, 25(6):e195-e202.
17. Rice D.P., Hodgson T.A., Kopstein A.N. The economic costs of illness: a replication and update. Health Care Financ Rev 1985, 7:61-80.
18. Haddix A.C., Teutsch S.M., Corso P.S. Prevention effectiveness: a guide to decision analysis and economic evaluation 2003, Oxford University Press, New York. 2nd edition.
19. Grover S., Ho V., Lavoie F., et al. The importance of indirect costs in primary cardiovascular disease prevention. Arch Intern Med 2003, 163:333-339.
20. Wang G., Pratt M., Macera C.A., et al. Physical activity, cardiovascular disease, and medical expenditures in U.S. adults. Ann Behav Med 2004, 28:88-94.
21. Samsa G.P., Bian J., Lipscomb J., et al. Epidemiology of recurrent cerebral infarction: a Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999, 30:338-349.
22. Sloan F.A., Taylor D.H., Picone G. Costs and outcomes of hip fracture and stroke, 1984 to 1994. Am J Public Health 1999, 89:935-937.
23. Amin S., Mullins C., Duncan B., et al. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. Am J Health Syst Pharm 1999, 56:1515-1520.
24. Garis R.I., Farmer K.C. Examining costs of chronic conditions in a Medicaid population. Manag Care 2002, 11:43-50.
25. Goetzel R., Long S., Ozminkowski R., et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004, 46:398-412.
26. Xuan J., Duong P.T., Russo P.A., et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000, 6:693-700.
27. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356:2388-2398.
28. Franco O., Peeters A., Looman C., et al. Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health 2005, 59:927-933.
29. Goldman L., Weinstein M.C., Goldman P.A., et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991, 265:1145-1151.
30. Johannesson M., Jönsson B., Kjekshus J., et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997, 336:332-336.
31. Prosser L., Stinnett A., Goldman P., et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. BMJ 1996, 312:1443.
32. Ashraf T., Hay J., Pitt B., et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996, 78:409-414.
33. Goldman L., Garber A.M., Grover S.A., et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996, 27:1020-1030.
34. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA 1998, 279:1615-1622.
35. Grover S.A., Paquet S., Levinton C., et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med 1998, 158:655-662.
36. Pletcher M.J., Lazar L., Domingo K., et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Int Med 2009, 150(4):243-254.
37. Pharoah P., Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996, 312(7044):1443-1448.
38. Ward S., Lloyd Jones M., Pandor A., et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007, 11(14):1-160.
39. Rich M., Nease R. Cost-effectiveness analysis in clinical practice. The case of health failure. Arch Intern Med 1999, 159:1690-1700.
40. Hamilton V., Racicot F.E., Zowall H., et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of raising HDL-C. JAMA 1995, 273:1032-1038.
41. Glick H., Heyse J.F., Thompson D., et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992, 8:719-734.
42. Kinosian B.P., Eisenberg J.M. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA 1988, 259:2249-2254.
43. Simpson R., Signorovitch J., Ramakrishnan K., et al. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk. Am J Ther 2010, [Epub ahead of print].
44. Gaspoz J., Coxson P., Goldman P., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002, 346:1800-1806.
45. Ades P., Pashkow F., Nestor J. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil 1997, 17(4):222-231.
46. Sanders G.D., Kong M.H., Al-Khatib S.M., et al. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. Am Heart J 2010, 160(1):122-131.
47. Kupersmith J., Rovner M., Hogan A., et al. Cost-effectiveness analysis in heart disease, part III: ischemia, congestive heart failure, and arrhythmias. Prog Cardiovasc Dis 1995, 37(5):307-346.
48. DeFrances C.J., Hall M.J. 2005 National Hospital Discharge Survey. Adv Data 2007, 1-19.
49. Singh A. Percutaneous coronary intervention vs coronary artery bypass grafting in the management of chronic stable angina: a critical appraisal. J Cardiovasc Dis Res 2010, 1(2):54-58.
50. Holmes J.S., Kozak L.J., Owings M.F. Use and in-hospital mortality associated with two cardiac procedures, by sex and age: national trends, 1990-2004. Health Aff (Millwood) 2007, 26:169-177.
51. Bravata D., Gienger A., McDonald K., et al. Systematic review: the comparative effectiveness of percutaneous coronary intervention and coronary artery bypass graft surgery. Ann Intern Med 2007, 147(10):703-716.
52. Stroupe K.T., Morrison D.A., Hlatky M., et al. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation 2006, 114:1251-1257.
53. Cohen D.J., Lavelle T.A., Hout B., et al. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or 3-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter Cardiovasc Interv 2011.
54. Serruys P.W., Unger F., Sousa E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001, 344:1117-1124.
55. Meeting minutes, December 8, 2006, Washington, DC US Food and Drug Administration, Circulatory System Devices Panel, Accessed September 21, 2011. http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4253t2.rtf.
56. Bischof M., Briel M., Bucher H.C., et al. Cost-effectiveness of drug-eluting stents in a US Medicare setting: a cost-utility analysis with 3-year clinical follow-up data. Value Health 2009, 12(5):649-656.
57. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009, 360(10):961-972.